No notable differences were observed between the two sets concerning age, menopausal status, family tumor history, HER2, ER, PR, Ki‐67 expression levels, T stage, lateralization and quadrant of breast lesions, and molecular subtypes (all p > 0.05). This evidence concerns the gene MKI67 and neoplasm.